{"id":"7d71af51-3797-5f06-8189-0556b23d9f71","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-top1-expression-null","predicate":"no_detected_change_in_recorded_comparison","statement":"Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"6d08873e-2161-5667-9cd8-0ccd5b142ed7","mechanism_event_label":"Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"3bf1c845-ddcc-5ae9-8a94-b592cdc76001","slug":"human-top1","display_name":"Human DNA topoisomerase I / TOP1","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"6d08873e-2161-5667-9cd8-0ccd5b142ed7","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-top1-expression-null-event","event_type":"experimental_observation","label":"Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.","description":"### api-top1-expression-null\n\nApigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.\nAbundance and enzyme activity are distinct endpoints.\nModel and exposure: Human HT-29 cells; 30–60 micromolar apigenin, 48 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin","sequence_order":0,"notes":""},{"entity":{"id":"3bf1c845-ddcc-5ae9-8a94-b592cdc76001","slug":"human-top1","display_name":"Human DNA topoisomerase I / TOP1","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin\", \"comparator\": \"Vehicle\", \"endpoint\": \"Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human HT-29 cells; 30–60 micromolar apigenin, 48 hours.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-top1-expression-null; Abundance and enzyme activity are distinct endpoints.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b5ed94a1-5b85-58c7-bf54-26801191b1ed","evidence_kind":"source_excerpt","locator":"Lines 716-722","start_line":716,"end_line":722,"excerpt":"### api-top1-expression-null\n\nApigenin did not detectably change TOP1 mRNA or protein in HT-29 cells despite the functional enzyme-assay effect.\nAbundance and enzyme activity are distinct endpoints.\nModel and exposure: Human HT-29 cells; 30–60 micromolar apigenin, 48 hours.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin directly interacts with and inhibits topoisomerase 1 to upregulate CD26/DPP4 on colorectal carcinoma cells. | 2022 | https://pubmed.ncbi.nlm.nih.gov/36618939/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC9815539/ | https://doi.org/10.3389/fphar.2022.1086894 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Human HT-29 cells; 30–60 micromolar apigenin, 48 hours.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}